0.32
-0.0288(-8.28%)
Currency In USD
Address
103 Carnegie Center Drive
Princeton, NJ 08540
United States of America
Phone
609 486 2308
Website
Sector
Healthcare
Industry
Biotechnology
Employees
163
First IPO Date
November 01, 2021
| Name | Title | Pay | Year Born |
| Mr. Adam Leo Stone | Interim Chief Executive Officer & Director | 0 | 1981 |
| Ms. Brianne Jahn | Chief Business Officer | 697,467 | 1986 |
| Ms. Ehong Gu | Interim Chief Financial Officer, Vice President & Head of Global Finance | 0 | N/A |
| Mr. Levvy Lv D. Eng | Senior Vice President & Global Head of Development | 0 | N/A |
| Dr. Michael Humphries M.D. | Chief Scientific Advisor | 0 | N/A |
| Ji Chen | Senior Vice President & General Counsel | 0 | N/A |
| Mr. Konstantin Poukalov | Founder & Executive Chairman | 0 | 1984 |
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.